SCHEMBL26911085

SCHEMBL26911085

C=CC(=O)Nc1cccc(-n2nc(-c3ccc(C(F)(F)F)cc3)c3ccccc32)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 2/20 0.61
▸ PTGER1 P34995 1/20 0.48
▸ TGM2 P21980 1/20 0.46
▸ MAPT P10636 6/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ MAP2K7 O14733 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ EGFR P00533 3/20 0.44
▸ LMNA P02545 2/20 0.43
▸ KDR P35968 2/20 0.43
▸ TEK Q02763 1/20 0.43
▸ EPHB4 P54760 1/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ TP53 P04637 2/20 0.42
▸ POLB P06746 1/20 0.40
▸ ROCK1 Q13464 1/20 0.40
▸ GSTO1 P78417 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30446277 1.00 BTK (0.61) BTKPTGER1TGM2MAPTMEN1
SCHEMBL30704741 0.90 BTK (0.50) BTKPTGER1TGM2MAPTMEN1
SCHEMBL26912332 0.90 BTK (0.50) BTKPTGER1TGM2MAPTMEN1
SCHEMBL26911652 0.89 BTK (0.49) BTKPTGER1TGM2MAPTMEN1
SCHEMBL30446347 0.89 BTK (0.49) BTKPTGER1TGM2MAPTMEN1
SCHEMBL26911512 0.88 BTK (0.48) BTKPTGER1TGM2MAPTMEN1
SCHEMBL30446349 0.88 BTK (0.48) BTKPTGER1TGM2MAPTMEN1
SCHEMBL30446340 0.86 BTK (0.51) BTKPTGER1TGM2MAPTEGFR
SCHEMBL26911322 0.86 BTK (0.51) BTKPTGER1TGM2MAPTEGFR
SCHEMBL30446993 0.86 BTK (0.52) BTKTGM2MAPTMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391779-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-12-07 — — US claimed
CN-115956080-A Bicyclic compounds, compositions containing them and their use 贝达药业股份有限公司 2023-04-11 — — CN claimed
US-20230391779-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-12-07 — — US disclosed
CN-115956080-A Bicyclic compounds, compositions containing them and their use 贝达药业股份有限公司 2023-04-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391779-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF CYP11B2, CYP11B1, CYP27A1 BTK 2459/4885PTGER1 431/4885TGM2 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback